Exousia Bio NT 10-Q Extension Filing - SEC Form 12b-25

NT 10-Q 1 exousia_nt10q.htm EXTENSION
| |
| |
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

| SEC FILE NUMBER: | 000-56599 |

| (Check One): | ☐ | Form 10-K | ☐ | Form 20-F | ☐ | Form 11-K | ☒ | Form 10-Q | ☐ | Form N-SAR | ☐ | Form N-CSR |

| | For Period Ended: February 28, 2026 | |
| | | |
| | ☐ | Transition Report on Form 10-K |
| | ☐ | Transition Report on Form 20-F |
| | ☐ | Transition Report on Form 11-K |
| | ☐ | Transition Report on Form 10-Q |
| | ☐ | Transition Report on Form N-SAR |
| | | |
| | For the Transition Period Ended: _____ | |

| Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein. |

If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates: __________

PART I -- REGISTRANT INFORMATION

| Exousia Bio, Inc. (formerly L A M Y) | |
| Full Name of Registrant | |
| | |
| | |
| Former Name if Applicable | |
| | |
| 7901 4th Street N #23494 | |
| Address of Principal Executive Office (Street and Number) | |
| | |
| St. Petersburg, Florida 33702 | |
| City, State and Zip Code | |

| |
| |

| |

| | | |

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

| | | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| | | | |
| ☒ | | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
| | | | |
| | | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

PART III – NARRATIVE

State below in reasonable detail the reasons why Forms 10-Q, 10-K,
20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.

The accountants could not complete the required financial statements,
the auditors could not complete their review of the financial statements and periodic report, and management could not complete the Management’s
Discussion and Analysis of such financial statements prior to the filing deadline.

PART IV-- OTHER INFORMATION

---

| (1) | Name and telephone number of person to contact in regard to this notification |

| Matthew Dwyer | | 509 | | 605-6553 |
| (Name) | | (Area Code) | | (Telephone Number) |

| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒     No ☐ |

| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐     No ☒ |

If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

| | 2 | |

| Exousia Bio, Inc. (formerly L A M Y)

(Name of Registrant as Specified in Charter) |

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

| Date: April 14, 2026 | By: /s/ Matthew Dwyer |
| | Matthew Dwyer

Chief Executive Officer and

Chief Financial Officer |

| | 3 | |